STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug

AstraZeneca and Ionis Pharmaceuticals reported that their heart disease drug, Wainua, failed in a pivotal trial for ATTR-CM, showing no improvement over placebo in reducing cardiovascular death and clinical events. The failure caused AstraZeneca's U.S. shares to drop 8% and London-listed shares to fall 9%, while Ionis shares fell 12%.